| Relistor (methylnaltrexone bromide) / Ono Pharma, Bausch Health |
ACTRN12611000002987: An open-label, pilot study to examine the pharmacokinetics, efficacy and safety of Methylnaltrexone Bromide in paediatric patients with opioid-induced constipation who have failed standard aperient treatment. |
|
|
| Not yet recruiting | 4 | 6 | | | The Royal Children's Hospital | Opioid-induced Constipation | | | | |
2012-003409-86: The effect of medication to reduce opioid adverse events on oesophageal sensitivity in healthy volunteers. |
|
|
| Ongoing | 4 | 10 | Europe | Naloxone, methylnaltrexone, Concentrate for solution for infusion, Concentrate for cutaneous solution, Naloxon, Relistor | KULeuven, KULeuven | Altered oesophageal sensitivity, Altered oesophageal sensitivity, Body processes [G] - Digestive System and Oral Physiological Phenomena [G10] | | | | |
2009-017193-20: Effect of naloxone and methylnaltrexone on satiety, gastric sensitivity, and accommodation to food in healthy volunteers. |
|
|
| Ongoing | 4 | 20 | Europe | Narcan, Relistor, Narcan, Relistor | UZLeuven | healthy volunteersnone; this is a physiological study to investigate the influence of opioid antagonism on gastric sensorimotor function | | | | |
2010-020520-22: ESTUDIO PILOTO RANDOMIZADO ABIERTO DE AHORRO DE MEDIDAS RECTALES EN ESTREÑIMIENTO OPIOIDE EN POBLACIÓN EN FASE TERMINAL MEDIANTE EL EMPLEO DE METILNALTREXONA SUBCUTANEA |
|
|
| Ongoing | 4 | 16 | Europe | RELISTOR 12 mg/0,6 ml, solución inyectable, RELISTOR 12 mg/0,6 ml, solución inyectable | Fundación para la Investigación Biomédica del Hospital Gregorio Marañón | ESTREÑIMIENTO OPIOIDE | | | | |
2010-020169-26: INFLUENCE OF NALOXONE AND METHYLNALTREXONE ON INTERDIGESTIVE GASTROINTESTINAL MOTILITY AND HUNGER SCORES IN MAN. |
|
|
| Ongoing | 4 | 20 | Europe | NALOXONE HYDROCLORIDE, RELISTOR, V03AB15, A06AH01, NARCAN, RELISTOR, NARCAN, RELISTOR | | healthy volunteersnone; this is a physiological study to investigate the influence of opioid antagonism on the interdigestive motor activity of the proximal gastrointestinal tract, hunger scores and plasma gastrointestinal hormone levels | | | | |
2016-000532-17: Effect of impaired stomach relaxation on reflux Het effect van onvolledige maagrelaxatie op reflux |
|
|
| Ongoing | 4 | 25 | Europe | Relistor 12 mg/0,6 ml oplossing voor injectie, Concentrate for cutaneous solution, Relistor 12 mg/0,6 ml oplossing voor injectie | K.U. Leuven, K.U. Leuven | Impaired gastric accommodation Onvolledige maagaccommodatie, Impaired stomach relaxation Onvolledige maagrelaxatie, Body processes [G] - Digestive System and Oral Physiological Phenomena [G10] | | | | |
NCT03523520: Methylnaltrexone vs Naloxegol in the Treatment of Opioid-Induced Constipation |
|
|
| Completed | 4 | 15 | US | Methylnaltrexone Bromide 150 mg Oral Tablet, Relistor, Methylnaltrexone Bromide 12 MG/0.6 ML Subcutaneous Solution [RELISTOR]_#1, Naloxegol 25 MG Oral Tablet, Movantik | University of Missouri-Columbia | Constipation Drug Induced | 03/23 | 03/23 | | |
NCT06162377: Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A "Window of Opportunity" Pilot Study. |
|
|
| Recruiting | 4 | 25 | US | Methylnaltrexone, Relistor™ | M.D. Anderson Cancer Center | Head and Neck Squamous Cell Carcinoma | 06/26 | 06/26 | | |
2008-005692-10: A Randomized, Double-blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Subjects With Cancer-Related PainEstudio aleatorizado, en doble ciego y controlado con placebo, para evaluar la seguridad y la eficacia de la metilnaltrexona subcutánea en el tratamiento del estreñimiento inducido por opiáceos en pacientes con dolor de origen tumoral |
|
|
| Ongoing | 3/4 | 36 | Europe | Methylnaltrexone bromide for SC injection: 8 mg (0.4 mL, 20 mg/mL) in prefilled syringes, Methylnaltrexone bromide for SC injection: 12 mg (0.6 mL, 20 mg/mL) in prefilled syringes, Methylnaltrexone bromide for SC injection: (0.6 mL, 20 mg/mL) in vials, MOA-728, | Wyeth Research Division of Wyeth Pharmaceuticals Inc. | Opioid-induced constipation in subjects with cancer-related painEstreñimiento inducido por opiáceos en pacientes con dolor de origen tumoral | | | | |
ACTRN12611001182987: Does blocking the body's own morphine-like chemicals during exercise change the perception of breathlessness? |
|
|
| Recruiting | 3 | 30 | | | Flinders University- Deptment of Palliative and Supportive Services, Flinders Medical Centre foundation, Mundipharma Pty Ltd | Breathlessness during exercise in people with Chronic Obstructive Pulmonary Disease. | | | | |
2008-005935-14: An Open-Label Study to Evaluate the Long-term Safety of Subcutaneous MOA-728 forTreatment of Opioid-Induced Constipation in Subjects With Nonmalignant PainEstudio abierto para evaluar la seguridad a largo plazo de MOA-728 subcutánea para el tratamiento del estreñimiento inducido por opiáceos en sujetos con dolor de origen no maligno |
|
|
| Ongoing | 3 | 72 | Europe | Methylnaltrexone bromide for SC injection: 12 mg (0.6 mL, 20 mg/mL) in prefilled syringes, MOA-728, | Wyeth Research Division of Wyeth Pharmaceuticals Inc. | Opioid-induced constipation in subjects with non-malignant painTratamiento del estreñimiento inducido por opiáceos en sujetos con dolor de origen no maligno | | | | |
| Completed | 2/3 | 105 | Europe | Placebo treatment, Methylnaltrexone treatment | Asbjørn Mohr Drewes, Odense University Hospital, Hvidovre University Hospital, University Hospital Bispebjerg and Frederiksberg | Acute Pancreatitis | 04/23 | 04/23 | | |
2004-004496-10: A Phase 2a double blind, randomised, placebo controlled, two dose study to determine the effect of orally administered methylnaltrexone (MNTX) in preventing post-operative opiate induced constipation in patients undergoing elective orthopaedic surgery |
|
|
| Ongoing | 2 | 36 | Europe | Coated Methylnaltrexone, MNTX, Capsule, hard | Norgine International Limited | Coated MNTX is being developed for the prevention of constipation in patients taking opioids for hip and knee replacement surgery for analgesia (pain relief). This drug is as yet unlicensed for use in humans. Studies in subjects have shown no adverse effects of oral doses of MNTX, indicating that oral MNTX is safe and well tolerated in healthy humans at doses of up to 19.2mg/kg. | | | | |
NCT04787848: Chronic Widespread Pain in HIV: Novel Mechanisms and Therapeutics |
|
|
| Recruiting | N/A | 200 | US | Relistor Injectable Product, Methylnaltrexone Bromide | University of Alabama at Birmingham | Chronic Widespread Pain | 06/25 | 12/25 | | |
| MCC22 / University of Minnesota |
| No trials found |
| tianeptine oxalate controlled release (TNX-601 CR) / Tonix |
| No trials found |
